
French biopharma, Osivax, has announced positive results from its phase 2 study, OVX836-004, into OVX836, its broad-spectrum influenza vaccine lead …

Osivax has announced the completion of patient visits in its phase 2a trial evaluating a booster dose of OVX836, a …

